SFINX-a Drug-drug Interaction Database Designed for Clinical Decision Support Systems

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2009 Feb 12

PMID 19205683

Citations 78

Authors

Ylva Bottiger

Kari Laine

Marine L Andersson

Tuomas Korhonen

Bjorn Molin

Marie-Louise Ovesjo

Tuire Tirkkonen

Anders Rane

Lars L Gustafsson

Birgit Eiermann

Affiliations

Soon will be listed here.

Abstract

Objective: The aim was to develop a drug-drug interaction database (SFINX) to be integrated into decision support systems or to be used in website solutions for clinical evaluation of interactions.

Methods: Key elements such as substance properties and names, drug formulations, text structures and references were defined before development of the database. Standard operating procedures for literature searches, text writing rules and a classification system for clinical relevance and documentation level were determined. ATC codes, CAS numbers and country-specific codes for substances were identified and quality assured to ensure safe integration of SFINX into other data systems. Much effort was put into giving short and practical advice regarding clinically relevant drug-drug interactions.

Results: SFINX includes over 8,000 interaction pairs and is integrated into Swedish and Finnish computerised decision support systems. Over 31,000 physicians and pharmacists are receiving interaction alerts through SFINX. User feedback is collected for continuous improvement of the content.

Conclusion: SFINX is a potentially valuable tool delivering instant information on drug interactions during prescribing and dispensing.

Citing Articles

Exploring the need for a clinical decision support system for deprescribing - A qualitative interview study.

Talani A, Hammar T, Bottiger Y Explor Res Clin Soc Pharm. 2025; 17:100574.

PMID: 39996042 PMC: 11848097. DOI: 10.1016/j.rcsop.2025.100574.

Pharmacotherapeutic actions related to drug interaction alerts - a questionnaire study among Swedish hospital interns and residents in family medicine.

Tukukino C, Parodi Lopez N, Lonnbro J, Wallerstedt S, Svensson S Eur J Clin Pharmacol. 2024; 81(2):301-308.

PMID: 39680076 PMC: 11717818. DOI: 10.1007/s00228-024-03785-4.

Potential Adverse Drug Events Identified with Decision Support Algorithms from Janusmed Risk Profile-A Retrospective Population-Based Study in a Swedish Region.

Hammar T, Jonsen E, Bjorneld O, Askfors Y, Andersson M, Lincke A Pharmacy (Basel). 2024; 12(6).

PMID: 39585094 PMC: 11587405. DOI: 10.3390/pharmacy12060168.

Apixaban plasma concentrations in patients with obesity.

Al-Aieshy F, Skeppholm M, Fyrestam J, Johansson F, Pohanka A, Malmstrom R Eur J Clin Pharmacol. 2024; 80(9):1343-1354.

PMID: 38822847 PMC: 11303434. DOI: 10.1007/s00228-024-03696-4.

Serious adverse drug events associated with psychotropic treatment of bipolar or schizoaffective disorder: a 17-year follow-up on the LiSIE retrospective cohort study.

Truedson P, Ott M, Wahlstrom L, Lundqvist R, Maripuu M, Lindmark K Front Psychiatry. 2024; 15:1358461.

PMID: 38633030 PMC: 11022285. DOI: 10.3389/fpsyt.2024.1358461.

References

Pai M, Graci D, Amsden G . Macrolide drug interactions: an update. Ann Pharmacother. 2000; 34(4):495-513. DOI: 10.1345/aph.19138. View

Shear N, Drake L, Gupta A, Lambert J, Yaniv R . The implications and management of drug interactions with itraconazole, fluconazole and terbinafine. Dermatology. 2000; 201(3):196-203. DOI: 10.1159/000018488. View

Thompson D, Oster G . Use of terfenadine and contraindicated drugs. JAMA. 1996; 275(17):1339-41. View

van der Sijs H, Aarts J, Vulto A, Berg M . Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc. 2005; 13(2):138-47. PMC: 1447540. DOI: 10.1197/jamia.M1809. View

Neuvonen P, Niemi M, Backman J . Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006; 80(6):565-81. DOI: 10.1016/j.clpt.2006.09.003. View

Bergk V, Haefeli W, Gasse C, Brenner H, Martin-Facklam M . Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol. 2005; 61(5-6):327-35. DOI: 10.1007/s00228-005-0943-4. View

Juurlink D, Mamdani M, Kopp A, Laupacis A, Redelmeier D . Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003; 289(13):1652-8. DOI: 10.1001/jama.289.13.1652. View

Grizzle A, Mahmood M, Ko Y, Murphy J, Armstrong E, Skrepnek G . Reasons provided by prescribers when overriding drug-drug interaction alerts. Am J Manag Care. 2007; 13(10):573-8. View

Tirkkonen T, Laine K . Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharmacol Ther. 2004; 76(6):639-47. DOI: 10.1016/j.clpt.2004.08.017. View

10.

Gronroos P, Irjala K, Huupponen R, Scheinin H, FORSSTROM J, Forsstrom J . A medication database--a tool for detecting drug interactions in hospital. Eur J Clin Pharmacol. 1997; 53(1):13-7. DOI: 10.1007/s002280050330. View

11.

Eliasson M, Bastholm P, Forsberg P, Henriksson K, Jacobson L, Nilsson A . Janus computerised prescribing system provides pharmacological knowledge at point of care - design, development and proof of concept. Eur J Clin Pharmacol. 2006; 62(4):251-8. DOI: 10.1007/s00228-006-0114-2. View

12.

Sindrup S, Brosen K, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo H . Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther. 1990; 48(6):686-93. DOI: 10.1038/clpt.1990.212. View

13.

Mitchell P . Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Saf. 1998; 17(6):390-406. DOI: 10.2165/00002018-199717060-00005. View

14.

Hesse L, von Moltke L, Greenblatt D . Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs. 2003; 17(7):513-32. DOI: 10.2165/00023210-200317070-00004. View

15.

Garg A, Adhikari N, McDonald H, Rosas-Arellano M, Devereaux P, Beyene J . Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA. 2005; 293(10):1223-38. DOI: 10.1001/jama.293.10.1223. View

16.

Bjerrum L, Andersen M, Petersen G, Kragstrup J . Exposure to potential drug interactions in primary health care. Scand J Prim Health Care. 2003; 21(3):153-8. DOI: 10.1080/02813430310001806. View

17.

Ahearn M, Kerr S . General practitioners' perceptions of the pharmaceutical decision-support tools in their prescribing software. Med J Aust. 2003; 179(1):34-7. DOI: 10.5694/j.1326-5377.2003.tb05415.x. View

18.

Lazarou J, Pomeranz B, Corey P . Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279(15):1200-5. DOI: 10.1001/jama.279.15.1200. View

19.

Heikkila T, Lekander T, Raunio H . Use of an online surveillance system for screening drug interactions in prescriptions in community pharmacies. Eur J Clin Pharmacol. 2006; 62(8):661-5. DOI: 10.1007/s00228-006-0149-4. View

20.

Sindrup S, Arendt-Nielsen L, Brosen K, Bjerring P, Angelo H, ERIKSEN B . The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol. 1992; 42(6):587-91. DOI: 10.1007/BF00265920. View